This page includes Regulatory news filings supplied by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Hamilton, Bermuda – 29 August 2018 – In a filing with the Bermuda Stock Exchange (“BSX”), Jazz Pharmaceuticals plc (Nasdaq: JAZZ) whose Secured Loan Notes are listed on the BSX announced its participation in two upcoming investor conferences. The full filing stated:
DUBLIN, August 29, 2018 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thecompany will be webcasting its corporate presentations at two upcoming investor conferences.
· Wells Fargo Securities Healthcare Conference in Boston, MA on Thursday, September6, 2018 at 8:35 a.m. EDT / 1:35 p.m. IST. Matt Young, executive vice president andchief financial officer, will provide an overview of the company and a business andfinancial update.
· Morgan Stanley 16th Annual Global Healthcare Conference in New York, NY onWednesday, September 12, 2018 at 8:45 a.m. EDT / 1:45 p.m. IST. Dan Swisher,president and chief operating officer, will provide an overview of the company and abusiness and financial update.
A live audio webcast of each presentation may be accessed from the Investors section of the JazzPharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the websiteprior to the start of the presentation to ensure adequate time for any software downloads that maybe necessary to listen to the webcast.
An archive of the webcast will be available for at least one week following the presentation on theInvestors section of the company’s website at http://www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focusedon improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and productcandidates with a focus in the areas of sleep and hematology/oncology. In these areas, JazzPharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginaseErwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine)liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countriesoutside the U.S. For country-specific product information, please visit http://www.jazzpharmaceuticals.com/products. For more information, please visit http://www.jazzpharmaceuticals.com/ and follow us on Twitter at @JazzPharma.
Jazz Pharmaceuticals Contacts:
Investors:
Kathee Littrell
Vice President, Investor RelationsIreland, +353 1 634 7887
U.S., +1 650 496 2717
Media:
Jacqueline Kirby
Vice President, Corporate Affairs & Government RelationsIreland, +353 1 697 2141
U.S., +1 215 867 4910